Forbion Capital Partners' arGEN-X completes IPO

Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners' portfolio company.

9 July 2014•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.